Insulet (NASDAQ:PODD) Price Target Raised to $400.00

Insulet (NASDAQ:PODD) had its price target boosted by Jefferies Financial Group from $375.00 to $400.00 in a research report report published on Thursday, Marketbeat Ratings reports. They currently have a buy rating on the medical instruments supplier’s stock.

A number of other equities research analysts have also issued reports on PODD. Zacks Research raised Insulet from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 14th. JPMorgan Chase & Co. increased their price objective on Insulet from $340.00 to $415.00 and gave the company an “overweight” rating in a research note on Friday, September 12th. Rothschild & Co Redburn boosted their target price on shares of Insulet from $350.00 to $370.00 and gave the company a “buy” rating in a research note on Friday, October 3rd. Leerink Partners upped their target price on shares of Insulet from $339.00 to $355.00 and gave the company an “outperform” rating in a report on Tuesday, October 14th. Finally, Oppenheimer increased their price target on Insulet from $324.00 to $365.00 and gave the stock an “outperform” rating in a research note on Monday, September 8th. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and a consensus target price of $370.76.

Insulet Trading Down 1.1%

Shares of PODD stock opened at $319.82 on Thursday. The stock has a market cap of $22.51 billion, a P/E ratio of 97.21, a P/E/G ratio of 2.64 and a beta of 1.39. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. Insulet has a fifty-two week low of $230.05 and a fifty-two week high of $353.50. The business has a fifty day simple moving average of $325.06 and a 200-day simple moving average of $309.86.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. The firm had revenue of $521.70 million for the quarter, compared to analysts’ expectations of $678.70 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm’s revenue was up 29.9% on a year-over-year basis. During the same period in the prior year, the company earned $1.08 EPS. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, analysts forecast that Insulet will post 3.92 earnings per share for the current fiscal year.

Insider Buying and Selling at Insulet

In related news, SVP Prem Singh sold 687 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the sale, the senior vice president directly owned 3,456 shares in the company, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Laetitia Cousin sold 797 shares of the firm’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the transaction, the senior vice president directly owned 3,890 shares in the company, valued at $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.39% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Insulet

Several institutional investors and hedge funds have recently modified their holdings of PODD. Larson Financial Group LLC lifted its position in Insulet by 426.3% during the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 81 shares in the last quarter. Zions Bancorporation National Association UT acquired a new stake in Insulet in the first quarter valued at approximately $26,000. SouthState Corp raised its stake in shares of Insulet by 253.3% during the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock valued at $28,000 after purchasing an additional 76 shares during the period. True Wealth Design LLC lifted its position in shares of Insulet by 288.0% during the third quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 72 shares in the last quarter. Finally, Kozak & Associates Inc. purchased a new position in shares of Insulet in the second quarter valued at $32,000.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.